Literature DB >> 19536125

Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

T A Skolarus1, J T Wei.   

Abstract

Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms among the aging male population. Epidemiological, pathophysiological and clinical studies indicate that many of these men also suffer from declining sexual function, especially those undergoing treatment for their BPH-related urinary symptoms. Although urinary symptoms and quality of life may improve with BPH therapy, the resulting effects on sexual function vary by medical, surgical and minimally invasive approaches and have not been consistently reported. As comprehensive, validated instruments to measure male sexual function are now available for routine use in the clinical setting, urologists and primary care providers caring for patients with BPH have the opportunity to monitor both urinary and sexual function before, during and after BPH therapy. Herein, we describe the relationship between BPH and its treatments on male sexual function, the role of new measures for sexual functioning and opportunities for future work to improve the care of men suffering from both maladies.

Entities:  

Mesh:

Year:  2009        PMID: 19536125      PMCID: PMC2862344          DOI: 10.1038/ijir.2009.26

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  97 in total

1.  Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.

Authors:  Alexandre R Zlotta; Xenofon Giannakopoulos; Odd Maehlum; Tonnes Ostrem; Claude C Schulman
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

2.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

3.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

Authors:  P Narayan; H Lepor
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

4.  Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.

Authors:  C C Schulman; J Cortvriend; U Jonas; T M Lock; S Vaage; M J Speakman
Journal:  Eur Urol       Date:  1999-12       Impact factor: 20.096

5.  Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

Authors:  J L Tenover; G A Pagano; A S Morton; C L Liss; C A Byrnes
Journal:  Clin Ther       Date:  1997 Mar-Apr       Impact factor: 3.393

6.  Sexual dysfunction in the United States: prevalence and predictors.

Authors:  E O Laumann; A Paik; R C Rosen
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

7.  Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

Authors:  Garry Welch; Katie Weinger; Michael J Barry
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

8.  Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.

Authors:  P Abrams; C C Schulman; S Vaage
Journal:  Br J Urol       Date:  1995-09

9.  An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.

Authors:  Man-Kay Li; Lester Garcia; Nelson Patron; Lei Chang Moh; Murali Sundram; Somboon Leungwattanakij; Choosak Pripatnanont; Christopher Cheng; Man Chi-Wai; Ngai Loi-Cheong
Journal:  BJU Int       Date:  2007-11-13       Impact factor: 5.588

10.  Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar.

Authors:  C A Byrnes; A S Morton; C L Liss; M C Lippert; J Y Gillenwater
Journal:  Clin Ther       Date:  1995 Sep-Oct       Impact factor: 3.393

View more
  1 in total

1.  Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report.

Authors:  Roger J Ziętek; Zbigniew M Ziętek
Journal:  Med Sci Monit       Date:  2021-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.